Please assess the completion status of the following clinical trial:

Trial Title: Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Confirmed SARS-CoV-2 viral infection~* Advanced COVID-19 with score of 3 or 4 on NIAID scale (first 40 patients) or score of 3 on NIAID scale (last 40 patient~* Has at least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath, confusion or severe lower respiratory symptoms~* Off antiviral medications at least 24 hours prior to first dose of study drug (except for remdesivir)~* Able to provide consent~* Agree to appropriate methods of contraception~Exclusion Criteria:~* In critical condition or has ARDS~* On invasive mechanical ventilation or ECMO~* Bacterial or fungal infection~* Pregnant or lactating (women)~* ALT \>5x ULN, bilirubin \>2x ULN, INR outside of normal limits at screening~* eGFR \<30 mL/min~* Clinically relevant serious co-morbid medical conditions~* Treatment with any immunosuppressive therapy within 30 days prior to screening~* Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to screening~* Prior treatment with the study drug (MMPD) or treatment with remdesivir more than 24 hours prior to the first randomized dose of study drug~* Known hypersensitivity to the inactive ingredients in the study drug (MMPD or placebo) or any ingredient of remdesivir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MMPD + remdesivir (Type: ACTIVE_COMPARATOR): Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
- Placebo + remdesivir (Type: PLACEBO_COMPARATOR): Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).